SEHK:867Pharmaceuticals
China Medical System Holdings (SEHK:867) Valuation After Desidustat Approval And Recent Share Price Pullback
China Medical System Holdings (SEHK:867) has secured Chinese regulatory approval for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis adult chronic kidney disease patients, expanding its presence in the nephrology segment.
See our latest analysis for China Medical System Holdings.
The share price is at HK$13.27 after a 1 day share price return of 2.47%. However, the 30 day share price return shows a 14.05% decline, which contrasts with an 82.01% 1 year total shareholder...